Figura 1. Conceptos de comorbilidad, multimorbilidad y carga de morbilidad. Las comorbilidades son cualquier enfermedad adicional a la enfermedad de estudio, y la combinación de todas ellas corresponde a la multimorbilidad. De la suma de ésta con diversos factores biológicos propios del paciente resulta la carga de morbilidad. Adaptado de [4].
Tabla. Prevalencia de comorbilidades específicas en pacientes con esclerosis múltiple, con estimaciones derivadas de estudios poblacionales. |
|||
Prevalencia |
Fuente |
||
Comorbilidades cardiovasculares |
Hipertensión arterial |
16-21% |
|
Dislipidemia |
~11% |
||
Diabetes mellitus de tipo II |
~8,5% |
[25] |
|
Enfermedad coronaria |
~2,5% |
||
Enfermedad cerebrovascular |
0,4-6,2% |
||
Comorbilidades gastrointestinales |
Enfermedad inflamatoria intestinal |
~3% |
[27] |
Enfermedad celíaca |
~11% |
[28] |
|
Comorbilidades pulmonares |
Asma |
~7,5% |
|
Enfermedad pulmonar crónica |
~10% |
||
Comorbilidades autoinmunitarias |
Diabetes mellitus de tipo I |
~1,6% |
|
Lupus eritematoso sistémico |
0,4-3% |
||
Psoriasis |
~7,7% |
[31] |
|
Artritis reumatoide |
~2,9% |
||
Vitíligo |
~0,1% |
[34] |
|
Comorbilidades endocrinas |
Enfermedad tiroidea |
~6% |
|
Cáncer |
Mama |
~2% |
[36] |
Estómago |
~0,02% |
[37] |
|
Colorrectal |
~0,17% |
[37] |
|
Cérvix |
~0,02% |
[36] |
|
Pulmón |
~0,5% |
[36] |
|
Cualquier cáncer |
~2,2% |
||
Comorbilidades neurológicas |
Epilepsia |
~3,1% |
|
Comorbilidades psiquiátricas |
Ansiedad |
~22% |
|
Depresión |
~24% |
||
Trastornos psicóticos |
~4,3% |
Figura 2. Representación esquemática de pacientes con esclerosis múltiple, que tienen comorbilidades y no las tienen. En los pacientes con comorbilidades, el diagnóstico (Dx) es más tardío, la tasa de brotes y de acumulación de discapacidad (EDSS) es más alta y la supervivencia es menor que en los pacientes sin comorbilidades. SCA: síndrome clínico aislado.
Prevalence and impact of comorbidities in patients with multiple sclerosis Introduction. Multiple sclerosis is a chronic, inflammatory and degenerative disease of the central nervous system. In most cases it is characterised by the recurring focal neurological deficit, which may become progressive over time. Given the chronic nature of the disease, patients may present with additional diseases (comorbidities), which affect the natural history of the disease and its treatment in different ways. Aim. To summarise the available evidence regarding the influence of comorbidities on the natural history of multiple sclerosis. Development. Patients with multiple sclerosis are at greater risk than the general population of developing both acute and chronic comorbidities. It has been shown that comorbidities can delay the diagnosis of multiple sclerosis after clinical onset, increase the rates of relapses and of accumulation of disability. Comorbidities also influence aspects of the choice of treatment and therapy adherence. Finally, comorbidities also increase the mortality rate and reduce the quality of life of patients with multiple sclerosis. Conclusions. Screening, diagnosis and treatment of comorbidities are a key aspect of caring for patients with multiple sclerosis to improve their long-term prognosis in terms of disability, quality of life and mortality. Key words. Burden of disease. Comorbidity. Disability. Multimorbidity. Multiple sclerosis. Natural history. |